Investigational Drug Details
| Drug ID: | D372 |
| Drug Name: | Tofogliflozin |
| Synonyms: | Tofogliflozin; Tofogliflozin anhydrous |
| Type: | Chemical drug |
| DrugBank ID: | DB11824 |
| DrugBank Description: | Tofogliflozin has been used in trials studying the treatment and prevention of Diabetes Mellitus Type 2. |
| PubChem ID: | 46908929 |
| CasNo: | 903565-83-3 |
| Repositioning for NAFLD: | No |
| SMILES: | O[C@H]1[C@]2(c3c(CO2)ccc(c3)Cc2ccc(cc2)CC)O[C@@H]([C@H]([C@@H]1O)O)CO |
| Structure: |
|
| InChiKey: | VWVKUNOPTJGDOB-BDHVOXNPSA-N |
| Molecular Weight: | 386.444 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | SGLT2 inhibitor |
| Therapeutic Category: | Improve insulin resistance |
| Clinical Trial Progress: | Clinical trial completed (JPRN-jRCTs031190040: SGLT2 inhibitors tended to reduce liver fat content and liver hardness compared to the control drug metformin, but the number of samples was small, individual differences were large, and statistically significant differences were not observed. Regarding safety, no serious adverse events were observed, and there was no need to change other therapeutic agents.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0066 | NCT02649465 | Phase 4 | Completed | No Results Available | November 11, 2015 | July 2, 2021 | Details |
| L0478 | JPRN-jRCTs031180159 | Not applicable | Not Recruiting | Has Results | 26/02/2019 | 10 January 2022 | Details |
| L0517 | JPRN-UMIN000030355 | Not applicable | Recruiting | No Results Available | 15/12/2017 | 17 May 2021 | Details |
| L0593 | JPRN-UMIN000020544 | Not selected | Not Recruiting | No Results Available | 13/01/2016 | 21 May 2019 | Details |
| L0740 | JPRN-jRCTs031190040 | Not applicable | Not Recruiting | Has Results | 17/06/2019 | 10 January 2022 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A03357 | 34029949 | Biomed Pharmacother | The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model. | Details |
| A04509 | 33593749 | BMJ Open Diabetes Res Care | Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. | Details |
| A08737 | 32006266 | Adv Exp Med Biol | Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. | Details |
| A08867 | 31956961 | Diabetes Ther | Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. | Details |
| A08869 | 31956725 | Contemp Clin Trials Commun | Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). | Details |
| A11228 | 30984539 | FEBS Open Bio | Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH). | Details |
| A15377 | 28938561 | Oncotarget | Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice. | Details |
| A28641 | 35203369 | Cells | Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis. | Details |
| A28693 | 35121372 | Biochem Biophys Res Commun | Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model. | Details |
| A42421 | 34572340 | Biomedicines | Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes. | Details |
| A49970 | 35578445 | Hepatol Commun | Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. | Details |
| A50745 | 35280867 | Front Med (Lausanne) | Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | Details |